Document Detail


Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
MedLine Citation:
PMID:  10517729     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Low-molecular-weight heparins are attractive alternatives to unfractionated heparin (UFH) for management of unstable angina/non-Q-wave myocardial infarction (UA/NQMI). METHODS AND RESULTS: Patients (n=3910) with UA/NQMI were randomized to intravenous UFH for >/=3 days followed by subcutaneous placebo injections or uninterrupted antithrombin therapy with enoxaparin during both the acute phase (initial 30 mg intravenous bolus followed by injections of 1.0 mg/kg every 12 hours) and outpatient phase (injections every 12 hours of 40 mg for patients weighing <65 kg and 60 mg for those weighing >/=65 kg). The primary end point (death, myocardial infarction, or urgent revascularization) occurred by 8 days in 14.5% of patients in the UFH group and 12.4% of patients in the enoxaparin group (OR 0.83; 95% CI 0.69 to 1.00; P=0. 048) and by 43 days in 19.7% of the UFH group and 17.3% of the enoxaparin group (OR 0.85; 95% CI 0.72 to 1.00; P=0.048). During the first 72 hours and also throughout the entire initial hospitalization, there was no difference in the rate of major hemorrhage in the treatment groups. During the outpatient phase, major hemorrhage occurred in 1.5% of the group treated with placebo and 2.9% of the group treated with enoxaparin (P=0.021). CONCLUSIONS: Enoxaparin is superior to UFH for reducing a composite of death and serious cardiac ischemic events during the acute management of UA/NQMI patients without causing a significant increase in the rate of major hemorrhage. No further relative decrease in events occurred with outpatient enoxaparin treatment, but there was an increase in the rate of major hemorrhage.
Authors:
E M Antman; C H McCabe; E P Gurfinkel; A G Turpie; P J Bernink; D Salein; A Bayes De Luna; K Fox; J M Lablanche; D Radley; J Premmereur; E Braunwald
Related Documents :
15111859 - Surgical disobliteration of postthrombotic deep veins--endophlebectomy--is feasible.
12475829 - Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality...
2205019 - Thrombin-antithrombin iii-complex & fibrin degradation products in plasma: surgery and ...
10505539 - Design, baseline characteristics, and preliminary clinical results of the organization ...
22674649 - Treatment of burn scars with the 1,550 nm nonablative fractional erbium laser.
11848459 - Risk of venous thromboembolism recurrence: high negative predictive value of d-dimer pe...
17120889 - Evaluation of postoperative spinal epidural hematoma after microendoscopic posterior de...
9689159 - Effect of etidronate treatment on bone mass of male nephrolithiasis patients with idiop...
23934169 - Six percent hydroxyethyl starch 130/0.4 (voluven®) versus 5% human serum albumin for v...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  100     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  1999 Oct 
Date Detail:
Created Date:  1999-11-04     Completed Date:  1999-11-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1593-601     Citation Subset:  AIM; IM    
Affiliation:
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. eantman@rics.bwh.harvard.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Aged
Angina, Unstable / complications,  drug therapy*,  surgery
Anticoagulants / administration & dosage,  adverse effects,  therapeutic use
Creatine Kinase / blood
Double-Blind Method
Electrocardiography
Emergencies
Enoxaparin / administration & dosage,  adverse effects,  therapeutic use*
Europe / epidemiology
Factor Xa / antagonists & inhibitors
Female
Fibrinolytic Agents / administration & dosage,  adverse effects,  therapeutic use*
Hemorrhage / chemically induced
Heparin / administration & dosage,  adverse effects,  therapeutic use*
Humans
Isoenzymes
Life Tables
Male
Middle Aged
Mortality
Myocardial Infarction / drug therapy*,  epidemiology,  etiology,  prevention & control,  surgery
Myocardial Revascularization / statistics & numerical data
North America / epidemiology
Partial Thromboplastin Time
Recurrence
Safety
South America / epidemiology
Thrombolytic Therapy* / adverse effects
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Enoxaparin; 0/Fibrinolytic Agents; 0/Isoenzymes; 9005-49-6/Heparin; EC 2.7.3.2/Creatine Kinase; EC 3.4.21.6/Factor Xa
Comments/Corrections
Comment In:
Circulation. 1999 Oct 12;100(15):1586-9   [PMID:  10517727 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality b...
Next Document:  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarctio...